SCHEMBL540597

SCHEMBL540597

C[C](C)C=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11023144 0.74
SCHEMBL9336301 0.70
SCHEMBL3826889 0.70
SCHEMBL9021433 0.67
SCHEMBL9021721 0.67
SCHEMBL20663310 0.62
SCHEMBL3904360 0.60
SCHEMBL2169129 0.59
SCHEMBL6860057 0.59
SCHEMBL22042138 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120251927-A1 HOLOGRAM-RECORDING MEDIUM KABUSHIKI KAISHA TOSHIBA (JP) 2012-10-04 US claimed
EP-0376218-B1 Racemization free attachment of amino acids to solid phase PERSEPTIVE BIOSYSTEMS INC (US) 1999-02-24 EP claimed
US-5187270-A Solid phase synthesis of peptides using the reaction product of an N-protected amino acid and a 2,4-dichlorophenyl (4-halo methylphenoxy)acetate; efficiency; purity; kinetics MILLIPORE CORPORATION (US) 1993-02-16 US claimed
EP-0376218-A2 Racemization free attachment of amino acids to solid phase PERSEPTIVE BIOSYSTEMS, INC. (US) 1990-07-04 EP claimed
US-20240226309-A1 HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB Synthorx, Inc. (US) 2024-07-11 US disclosed
EP-4395901-A1 COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION Molecular Axiom, LLC (US) 2024-07-10 EP disclosed
EP-4396349-A1 COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION Molecular Axiom, LLC (US) 2024-07-10 EP disclosed
US-20240218027-A1 NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE 2024-07-04 US disclosed
CN-112105627-B Unnatural base pair compositions and methods of use 斯克利普斯研究所 2024-07-02 CN disclosed
WO-2024137864-A1 CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES Synthorx, Inc. (US) 2024-06-27 WO disclosed
WO-2024137991-A2 ENGINEERED GUIDE RNAS AND POLYNUCLEOTIDES SHAPE THERAPEUTICS INC. (US) 2024-06-27 WO disclosed
WO-2024136899-A1 CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES Synthorx, Inc. (US) 2024-06-27 WO disclosed
US-5817603-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-10-06 US disclosed
US-5807897-A MUSCULAR DISORDERS ZENECA LIMITED (GB) 1998-09-15 US disclosed
US-4897416-A 5-OXIMINO-13B-CARBONYLTHIOMILBEMYCIN DERIVATIVES CIBA-GEIGY CORPORATION (US) 1990-01-30 US disclosed
EP-0279783-A1 Insecticides and parasiticides CIBA-GEIGY AG (CH) 1988-08-24 EP disclosed
US-4374765-A Mammalian collagenase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1983-02-22 US disclosed
US-4371466-A Mammalian collagenase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1983-02-01 US disclosed
US-4371465-A Mammalian collagenase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1983-02-01 US disclosed
US-4093609-A Somatostatin synthesis AMERICAN HOME PRODUCTS CORPORATION (US) 1978-06-06 US disclosed